[go: up one dir, main page]

AR040281A2 - Proceso para la preparacion de composiciones de un inhibidor de glucogeno fosforilasa y forma de dosificacion - Google Patents

Proceso para la preparacion de composiciones de un inhibidor de glucogeno fosforilasa y forma de dosificacion

Info

Publication number
AR040281A2
AR040281A2 ARP030102181A ARP030102181A AR040281A2 AR 040281 A2 AR040281 A2 AR 040281A2 AR P030102181 A ARP030102181 A AR P030102181A AR P030102181 A ARP030102181 A AR P030102181A AR 040281 A2 AR040281 A2 AR 040281A2
Authority
AR
Argentina
Prior art keywords
amorphous
forming
polymer
solid
particles
Prior art date
Application number
ARP030102181A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR040281A2 publication Critical patent/AR040281A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un proceso para formar una composición farmacéutica de un compuesto inhibidor de glucógeno fosforilasa que comprende los pasos de (a) formar partículas de dispersión, amorfas, sólidas, cada una de las cuales comprende un fármaco ligeramente soluble y un polímero que aumenta la concentración; donde por lo menos una porción principal de dicho fármaco es amorfa; (b) mezclar dichas partículas de dispersión, amorfas, sólidas y material de matriz para formar una mezcla; (c) enfriar dicha mezcla fundida y formar partículas sólidas, comprendiendo cada una dichas partículas de dispersión, amorfas, sólidas y dicho material matriz: Se describe también forma de dosificación de estos compuestos capaces de suprimir la producción de glucosa hepática útiles para el tratamiento de la diabetes. Reivindicación 5: Un proceso para formar una composición farmacéutica, caracterizado porque comprende los pasos de: (a) formar una solución que comprende un fármaco ligeramente soluble, un polímero que aumenta la concentración y un disolvente; (b) secar por pulverización dicha solución bajo condiciones en las cuales dicha solución se atomiza para formar gotas cuyo tamano varía entre 1 a 500micrómetros, dichas gotas se solidifican para formar dichas partículas de dispersión, amorfas, sólidas que comprenden dicho fármaco y dicho polímero que aumenta la concentración ;,y (c) secar nuevamente dichas partículas de dispersión, amorfas, sólidas en un aparato de secado por separado para remover el disolvente residual. Reivindicación 11: El proceso de cualquiera de las reivindicaciones 4-10, caracterizado porque comprende además un excipiente adicional seleccionado del grupo compuesto por un agente tensioactivo, un polímero hinchable en agua, un polímero soluble en agua y un soluto hidrófobo.
ARP030102181A 2000-03-16 2003-06-19 Proceso para la preparacion de composiciones de un inhibidor de glucogeno fosforilasa y forma de dosificacion AR040281A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19012500P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
AR040281A2 true AR040281A2 (es) 2005-03-23

Family

ID=22700102

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010101186A AR028253A1 (es) 2000-03-16 2001-03-14 Inhibidores de la glucogeno fosforilasa
ARP030102181A AR040281A2 (es) 2000-03-16 2003-06-19 Proceso para la preparacion de composiciones de un inhibidor de glucogeno fosforilasa y forma de dosificacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010101186A AR028253A1 (es) 2000-03-16 2001-03-14 Inhibidores de la glucogeno fosforilasa

Country Status (16)

Country Link
US (2) US20010053791A1 (es)
EP (1) EP1263433A2 (es)
JP (2) JP2003526666A (es)
AR (2) AR028253A1 (es)
AU (1) AU2001240978A1 (es)
CA (1) CA2403233A1 (es)
CO (1) CO5271644A1 (es)
GT (1) GT200100039A (es)
MX (1) MXPA02009098A (es)
PA (1) PA8513701A1 (es)
PE (1) PE20011268A1 (es)
SV (1) SV2002000342A (es)
TN (1) TNSN01041A1 (es)
TW (1) TW200304377A (es)
UY (1) UY26615A1 (es)
WO (1) WO2001068092A2 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000238A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
CN1259909C (zh) * 2002-01-16 2006-06-21 兴和株式会社 含有2,2－二氯－12－(4－氯苯基)－十二烷酸的药物组合物
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
BR0307344A (pt) 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
PL373914A1 (en) * 2002-02-01 2005-09-19 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
PL371593A1 (en) * 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
ATE443041T1 (de) * 2002-07-11 2009-10-15 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8974823B2 (en) * 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
US20110027357A1 (en) * 2004-02-18 2011-02-03 Isaac Gilinski Compositions and methods for timed release of water-soluble nutritional supplements
US8158138B1 (en) * 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
ATE409462T1 (de) * 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
JP2008501802A (ja) * 2004-06-08 2008-01-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 医薬組成物
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
PT1855652E (pt) 2005-01-28 2016-01-26 Bend Res Inc Secagem de partículas contendo fármacos
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
WO2006128471A2 (en) * 2005-06-03 2006-12-07 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
AU2007226984B2 (en) 2006-03-20 2013-02-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP2090298A4 (en) * 2006-11-13 2014-02-26 Kyorin Seiyaku Kk METHOD FOR PRODUCING A TABLET WITH DELAYED RELEASE
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CN101835492B (zh) 2007-08-21 2012-11-21 德克萨斯州立大学董事会 用于制药应用的热动力学混合
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8518381B2 (en) 2008-03-28 2013-08-27 The Procter & Gamble Company Processes of making oral compositions containing gel networks
US20110123627A1 (en) * 2008-04-15 2011-05-26 Larry Yun Fang High density compositions containing posaconazole and formulations comprising the same
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
JP5757681B2 (ja) * 2009-08-12 2015-07-29 富士フイルム株式会社 セルロース誘導体、樹脂組成物、成形体及びその製造方法並びに電気電子機器用筐体
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
EP2389934A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
CA2818249C (en) * 2010-11-24 2021-04-13 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions comprising radezolid, hydroxypropylmethyl cellulose polymer, and a physical mixture
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9713594B2 (en) 2012-09-11 2017-07-25 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
EP2964243B1 (en) 2013-03-06 2022-11-23 Capsugel Belgium NV Curcumin solid lipid particles and methods for their preparation and use
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
EP3209960A1 (en) * 2014-10-23 2017-08-30 Bend Research, Inc. Spray nozzle and process for making nanoparticles
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
CN110475557B (zh) * 2017-01-20 2023-06-20 星座制药公司 固体分散体
CA3153332A1 (en) 2019-10-16 2021-04-22 Aouatef Bellamine Method and composition for increasing muscle protein synthesis
CN114867363A (zh) 2019-12-10 2022-08-05 比利时胶囊公司 含脂质基质核心和活性成分的颗粒
WO2022132676A1 (en) * 2020-12-16 2022-06-23 Merck Sharp & Dohme Corp. Mini-tablet dosage form of a viral terminase inhibitor and uses thereof
WO2025193777A1 (en) 2024-03-13 2025-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of alpha-1 antitrypsin modulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146A (en) * 1843-06-24 Improvement in friction-matches
US27614A (en) * 1860-03-27 Improvement in cultivators
US31547A (en) * 1861-02-26 Improvement in polishing iron bars and rods
DE3887179T2 (de) 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US4999200A (en) 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
ATE108996T1 (de) 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
JP3155028B2 (ja) 1991-06-10 2001-04-09 大川原化工機株式会社 噴霧乾燥造粒装置
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE4220782A1 (de) 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6254889B1 (en) * 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP3585654B2 (ja) 1996-07-11 2004-11-04 株式会社パウダリングジャパン ２段乾燥式スプレードライヤー装置
DK0922464T3 (da) 1996-07-12 2005-06-06 Daiichi Seiyaku Co Hurtigt desintegrerbare, kompressionsstöbte materialer og fremgangsmåder til fremstilling af samme
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
JP2000072676A (ja) 1998-09-01 2000-03-07 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6296149B1 (en) 1999-04-16 2001-10-02 Depuy Orthopaedics, Inc. Monomer delivery device for bone cement delivery system
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
GEP20043334B (en) 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
TR200201617T2 (tr) * 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
JP2003526666A (ja) 2003-09-09
TW200304377A (en) 2003-10-01
US20030185891A1 (en) 2003-10-02
UY26615A1 (es) 2001-10-25
PE20011268A1 (es) 2001-12-12
CA2403233A1 (en) 2001-09-20
US20010053791A1 (en) 2001-12-20
GT200100039A (es) 2001-12-31
US7235260B2 (en) 2007-06-26
TNSN01041A1 (fr) 2005-11-10
MXPA02009098A (es) 2003-03-12
EP1263433A2 (en) 2002-12-11
PA8513701A1 (es) 2002-10-24
AR028253A1 (es) 2003-04-30
JP2007182449A (ja) 2007-07-19
WO2001068092A3 (en) 2002-03-21
CO5271644A1 (es) 2003-04-30
WO2001068092A2 (en) 2001-09-20
SV2002000342A (es) 2002-07-16
AU2001240978A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
AR040281A2 (es) Proceso para la preparacion de composiciones de un inhibidor de glucogeno fosforilasa y forma de dosificacion
Purvis et al. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process
KR101638643B1 (ko) 새로운 제어 방출 활성 물질 담체
Attama et al. In vitro evaluation of drug release from self micro-emulsifying drug delivery systems using a biodegradable homolipid from Capra hircus
JP2002530317A5 (es)
ES2543427T3 (es) Forma farmacéutica oral de deferasirox
EP0241469B1 (de) Teilchen aus einer hydrophoben oder schwerlöslichen substanz und verfahren zu ihrer hydrophilisierung
KR970706801A (ko) 용융성(fusible) 담체를 함유하는 약제학적 조성물 및 그 제조방법(PHARMACEUTICAL COMPOSITIONS AND METHOD OF PRODUCING THE SAME)
EP1893176B1 (de) Herstellung von festen lösungen schwerlöslicher wirkstoffe durch kurzzeitüberhitzung und schnelle trocknung
Bhairav et al. Review on solubility enhancement techniques
WO2010102245A1 (en) Solid dispersion comprising resveratrol
ES2168855T3 (es) Composiciones farmaceuticas en forma de microparticulas polimericas obtenidas por extrusion y esferoidizacion.
WO2019233375A1 (zh) 一种氨基酸自组装超分子聚合物及其制备和应用
FR2547501A1 (fr) Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants
WO2003061627A1 (en) New process 1
EP1901716B1 (fr) Procédé de production de granulés contenant des particules cristallines de xylitol avec un autre polyol
Nithyashree et al. Floating microballoon-a novel formulation for gastrointestinal diseases
EP0116182B1 (fr) Procédé de préparation d'acide p-butoxyphénylacéthydroxamique à l'état finement divisé
Venkateswaramurthy et al. Design and evaluation of controlled release mucoadhesive microspheres of amoxicillin for anti Helicobacter pylori therapy
RU2005104423A (ru) Стабилизация профиля высвобождения активного вещества из лекарственной формы
JPH09202727A (ja) 溶解性に優れたカプセル粒子
CN104382859A (zh) 一种slgt2抑制剂颗粒及其制备方法
US20210121405A1 (en) Methods for Formulating an API, Composite Materials, and Solid Unit Dosage Forms
Awolaru et al. An in vitro Study of the Effect of Some Commonly Used Antacids on the Release Profile of Paracetamol and Metronidazole Tablets
KR102096864B1 (ko) 탄화수소를 이용한 나노수준의 활성물질 입자 제조방법

Legal Events

Date Code Title Description
FB Suspension of granting procedure